nach oben

coloproctology

Erschienen in:

05.01.2017 | Rektumkarzinom | Übersichten

Complete response nach Radiochemotherapie des Rektumkarzinoms – was tun?

verfasst von: PD Dr. med. D. Wilhelm, U. Nitsche, T. Vogel, K. P. Janssen, H. Friess

Erschienen in: coloproctology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die alleinige Beobachtung im Fall einer klinischen kompletten Tumorregression (cCR) nach neoadjuvanter Radiochemotherapie des Rektumkarzinoms wird zunehmend diskutiert. Grund hierfür sind Fallserien, die über lokale und systemische Tumorkontrollen berichten, die denen nach radikaler Chirurgie nahezu ebenbürtig sind, ohne das Risiko eines operativen Eingriffs oder einer permanenten Kolostomie zu beinhalten. Die vorliegende Arbeit ist bemüht, auf dem Boden der aktuellen Datenlage das Watch-and-wait-Konzept kritisch zu bewerten und in seiner Bedeutung gegenüber gängigen Methoden zu beurteilen.

Habr-Gama A, Perez RO, Nadalin W et al (2004) Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 240:711–717PubMedPubMedCentral

Appelt AL, Ploen J, Harling H et al (2015) High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: A prospective observational study. Lancet Oncol 16:919–927CrossRefPubMed

Smith RK, Fry RD, Mahmoud NN, Paulson EC (2015) Surveillance after neoadjuvant therapy in advanced rectal cancer with complete clinical response can have comparable outcomes to total mesorectal excision. Int J Colorectal Dis 30:769–774CrossRefPubMed

Araujo RO, Valadao M, Borges D et al (2015) Nonoperative management of rectal cancer after chemoradiation opposed to resection after complete clinical response. A comparative study. Eur J Surg Oncol 41:1456–1463CrossRefPubMed

Maas M, Beets-Tan RG, Lambregts DM et al (2011) Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol 29:4633–4640CrossRefPubMed

Li J, Liu H, Yin J et al (2015) Wait-and-see or radical surgery for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy: a cohort study. Oncotarget 6:42354–42361PubMedPubMedCentral

Petrelli F, Sgroi G, Sarti E, Barni S (2016) Increasing the interval between Neoadjuvant Chemoradiotherapy and surgery in rectal cancer: A Meta-analysis of published studies. Ann Surg 263:458–464CrossRefPubMed

Habr-Gama A, Gama-Rodrigues J, Sao Juliao GP et al (2014) Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: Impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys 88:822–828CrossRefPubMed

Lim L, Chao M, Shapiro J et al (2007) Long-term outcomes of patients with localized rectal cancer treated with chemoradiation or radiotherapy alone because of medical inoperability or patient refusal. Dis Colon Rectum 50:2032–2039CrossRefPubMed

10.

McKeown E, Nelson DW, Johnson EK et al (2014) Current approaches and challenges for monitoring treatment response in colon and rectal cancer. J Cancer 5:31–43CrossRefPubMedPubMedCentral

11.

Williamson JS, Jones HG, Davies M et al (2014) Outcomes in locally advanced rectal cancer with highly selective preoperative chemoradiotherapy. Br J Surg 101:1290–1298CrossRefPubMed

12.

Rodel C, Graeven U, Fietkau R et al (2015) Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): Final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 16:979–989CrossRefPubMed

13.

Hall MD, Schultheiss TE, Smith DD, Fakih MG, Wong JY, Chen YJ (2016) Effect of increasing radiation dose on pathologic complete response in rectal cancer patients treated with neoadjuvant chemoradiation therapy. Acta Oncol (Madr) 55:1392–1399CrossRef

14.

Hofheinz RD, Wenz F, Post S et al (2012) Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: A randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 13:579–588CrossRefPubMed

15.

Renehan AG, Malcomson L, Emsley R et al (2016) Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): A propensity-score matched cohort analysis. Lancet Oncol 17:174–183CrossRefPubMed

16.

Sloothaak DA, Geijsen DE, van Leersum NJ et al (2013) Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg 100:933–939CrossRefPubMed

17.

Ptok H, Ruppert R, Stassburg J et al (2013) Pretherapeutic MRI for decision-making regarding selective neoadjuvant radiochemotherapy for rectal carcinoma: interim analysis of a multicentric prospective observational study. J Magn Reson Imaging 37:1122–1128CrossRefPubMed

18.

Sathyakumar K, Chandramohan A, Masih D, Jesudasan MR, Pulimood A, Eapen A (2016) Best MRI predictors of complete response to neoadjuvant chemoradiation in locally advanced rectal cancer. Br J Radiol 89:20150328CrossRefPubMed

19.

Chen YG, Chen MQ, Guo YY, Li SC, Wu JX, Xu BH (2016) Apparent diffusion coefficient predicts pathology complete response of rectal cancer treated with Neoadjuvant Chemoradiotherapy. PLOS ONE 11:e0153944CrossRefPubMedPubMedCentral

20.

Memon S, Lynch AC, Bressel M, Wise AG, Heriot AG (2015) Systematic review and meta-analysis of the accuracy of MRI and endorectal ultrasound in the restaging and response assessment of rectal cancer following neoadjuvant therapy. Colorectal Dis 17:748–761CrossRefPubMed

21.

Hiotis SP, Weber SM, Cohen AM et al (2002) Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: An analysis of 488 patients. J Am Coll Surg 194:131–135CrossRefPubMed

22.

Lim SG, Kim YB, Oh SY (2016) Clinical significance of the endoscopic finding in predicting complete tumor response to preoperative Chemoradiation therapy in rectal cancer. World J Surg 40:3029–3034CrossRefPubMed

23.

Curvo-Semedo L, Lambregts DM, Maas M et al (2011) Rectal cancer: assessment of complete response to preoperative combined radiation therapy with chemotherapy – conventional MR volumetry versus diffusion-weighted MR imaging. Radiology 260:734–743CrossRefPubMed

24.

Ryan JE, Warrier SK, Lynch AC, Heriot AG (2015) Assessing pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: A systematic review. Colorectal Dis 17:849–861CrossRefPubMed

25.

Sanchez Loria F, Iseas S, O’Connor JM et al (2016) Non-surgical management of rectal cancer. Series of 68 cases, long follow up in two leading centres in Argentina. Dig Liver Dis 48:1372–1377CrossRefPubMed

26.

Habr-Gama A, Sabbaga J, Gama-Rodrigues J et al (2013) Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: Are we getting closer to anal cancer management? Dis Colon Rectum 56:1109–1117CrossRefPubMed

27.

Nahas SC, Rizkallah Nahas CS, Sparapan Marques CF et al (2016) Pathologic complete response in rectal cancer: Can we detect it? Lessons learned from a proposed randomized trial of watch-and-wait treatment of rectal cancer. Dis Colon Rectum 59:255–263CrossRefPubMed

28.

Kreis ME, Ruppert R, Ptok H et al (2016) Use of preoperative magnetic resonance imaging to select patients with rectal cancer for Neoadjuvant Chemoradiation – Interim analysis of the German OCUM trial (NCT01325649). J Gastrointest Surg 20:25–32CrossRefPubMed

29.

Lefevre JH, Mineur L, Kotti S et al (2016) Effect of interval (7 or 11 weeks) between Neoadjuvant Radiochemotherapy and surgery on complete pathologic response in rectal cancer: A Multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol. doi:10.1200/JCO.2016.67.6049 PubMed

30.

Armstrong D, Raissouni S, Price Hiller J et al (2015) Predictors of pathologic complete response after Neoadjuvant treatment for rectal cancer: A Multicenter study. Clin Colorectal Cancer 14:291–295CrossRefPubMed

31.

Hur H, Kim NK, Min BS et al (2014) Can a biomarker-based scoring system predict pathologic complete response after preoperative chemoradiotherapy for rectal cancer? Dis Colon Rectum 57:592–601CrossRefPubMed

32.

Maas M, Nelemans PJ, Valentini V et al (2010) Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: A pooled analysis of individual patient data. Lancet Oncol 11:835–844CrossRefPubMed

33.

Gavioli M, Luppi G, Losi L et al (2005) Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer. Dis Colon Rectum 48:1851–1857CrossRefPubMed

34.

de Campos-Lobato LF, Stocchi L, da Luz Moreira A et al (2011) Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence. Ann Surg Oncol 18:1590–1598CrossRefPubMed

35.

Andrade VA, Coy CS, Leal RF, Fagundes JJ, Martinez CA, Ayrizono Mde L (2016) Neoadjuvant therapy and surgery for rectal cancer. Comparative study between partial and complete pathological response. Arq Gastroenterol 53:163–168CrossRefPubMed

36.

Bosch SL, Vermeer TA, West NP et al (2016) Clinicopathological characteristics predict lymph node metastases in ypT0-2 rectal cancer after chemoradiotherapy. Histopathology 69:839–848CrossRefPubMed

37.

Hughes R, Glynne-Jones R, Grainger J et al (2006) Can pathological complete response in the primary tumour following pre-operative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for sterilisation of pelvic lymph nodes, a low risk of local recurrence and the appropriateness of local excision? Int J Colorectal Dis 21:11–17CrossRefPubMed

38.

Taylor FG, Quirke P, Heald RJ et al (2011) Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: A prospective, multicenter, European study. Ann Surg 253:711–719CrossRefPubMed

39.

Smith JD, Ruby JA, Goodman KA et al (2012) Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. Ann Surg 256:965–972CrossRefPubMed

40.

Martens MH, Maas M, Heijnen LA et al (2016) Long-term outcome of an organ preservation program after Neoadjuvant treatment for rectal cancer. J Natl Cancer Inst 108(12). doi:10.1093/jnci/djw171

41.

Li J, Li L, Yang L et al (2016) Wait-and-see treatment strategies for rectal cancer patients with clinical complete response after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis. Oncotarget 7:44857–44870PubMedPubMedCentral

42.

Kim HJ, Song JH, Ahn HS et al (2016) Wait and see approach for rectal cancer with a clinically complete response after neoadjuvant concurrent chemoradiotherapy. Int J Colorectal Dis. doi:10.1007/s00384-016-2709-0

43.

Callender GG, Das P, Rodriguez-Bigas MA et al (2010) Local excision after preoperative chemoradiation results in an equivalent outcome to total mesorectal excision in selected patients with T3 rectal cancer. Ann Surg Oncol 17:441–447CrossRefPubMed

44.

Belluco C, De Paoli A, Canzonieri V et al (2011) Long-term outcome of patients with complete pathologic response after neoadjuvant chemoradiation for cT3 rectal cancer: Implications for local excision surgical strategies. Ann Surg Oncol 18:3686–3693CrossRefPubMedPubMedCentral

45.

Dimitriou N, Michail O, Moris D, Griniatsos J (2015) Low rectal cancer: Sphincter preserving techniques-selection of patients, techniques and outcomes. World J Gastrointest Oncol 7:55–70CrossRefPubMedPubMedCentral

46.

Walega P, Kenig J, Richter P, Nowak W (2010) Functional and clinical results of transanal endoscopic microsurgery combined with endoscopic posterior mesorectum resection for the treatment of patients with t1 rectal cancer. World J Surg 34:1604–1608CrossRefPubMed

47.

Habr-Gama A, Lynn PB, Jorge JM et al (2016) Impact of organ-preserving strategies on Anorectal function in patients with distal rectal cancer following Neoadjuvant Chemoradiation. Dis Colon Rectum 59:264–269CrossRefPubMed

48.

Bosset JF, Calais G, Mineur L et al (2014) Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: Long-term results of the EORTC 22921 randomised study. Lancet Oncol 15:184–190CrossRefPubMed

49.

Garcia-Aguilar J, Chow OS, Smith DD et al (2015) Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: A multicentre, phase 2 trial. Lancet Oncol 16:957–966CrossRefPubMedPubMedCentral

50.

Breugom AJ, Swets M, Bosset JF et al (2015) Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: A systematic review and meta-analysis of individual patient data. Lancet Oncol 16:200–207CrossRefPubMed

51.

Bonjer HJ, Deijen CL, Haglind E, Group CIS (2015) A randomized trial of Laparoscopic versus open surgery for rectal cancer. N Engl J Med 373:194PubMed

Titel: Complete response nach Radiochemotherapie des Rektumkarzinoms – was tun?
verfasst von: PD Dr. med. D. Wilhelm
U. Nitsche
T. Vogel
K. P. Janssen
H. Friess
Publikationsdatum: 05.01.2017
Verlag: Springer Medizin
Schlagwörter: Rektumkarzinom
Rektumkarzinom
Erschienen in: coloproctology / Ausgabe 2/2017
Print ISSN: 0174-2442
Elektronische ISSN: 1615-6730
DOI: https://doi.org/10.1007/s00053-016-0128-x

Passend zum Thema

Synergien nutzen gegen Tumore

Magenkarzinom

Lungen- und Magentumore können dank Immuntherapien deutlich besser behandelt werden. Dennoch kommt es trotzdem weiterhin häufig zum Krankheitsprogress. Welche Therapieoptionen sich in der Zweitlinie am besten eignen, haben wir für Sie zusammengefasst.

Darmkrebsreihenuntersuchungen zeigen EU-weit Erfolge

Kolonkarzinom

In Europa haben viele Länder dem Darmkrebs mit Hilfe von Früherkennungsprogrammen den Kampf angesagt. Es gibt einen deutlichen Zusammenhang zwischen Inzidenz und Mortalität von Darmkrebs und der Zeitspanne seit Einführung von Reihenuntersuchungen.

GI-Tumore und die Rolle von Angiogenesehemmern

Content Hub

Entdecken Sie mit praxisrelevanten Patientenfällen, kompakten Studieninhalten, informativen Experteninterviews und weiteren spannenden Inhalten, wie Sie den vielseitigen Herausforderungen bei GI-Tumoren begegnen können. Hier erfahren Sie mehr! _{PP-RB-DE-2009}

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Gatekeeper™ – eine effektive Option zur Therapie der Stuhlinkontinenz?

Fettgewebsstammzellen (Cx601) für komplexe perianale Crohn-Fisteln (Phase III RCT)

Mitteilungen des BCD und der DGK

Metaanalysen zur transanalen totalen mesorektalen Exzision

43. Deutscher Koloproktologen-Kongress

Are gut bacteria associated with the development of anastomotic leaks?

Passend zum Thema

Synergien nutzen gegen Tumore

Darmkrebsreihenuntersuchungen zeigen EU-weit Erfolge

GI-Tumore und die Rolle von Angiogenesehemmern